Gastrointestinal (GI) pythiosis is a severe and often fatal disease in dogs that traditionally has been poorly responsive to medical treatment. Although aggressive surgical resection with wide margins is the most consistently effective treatment, lesion location and extent often preclude complete resection. Recently, it has been suggested that the addition of anti-inflammatory doses of corticosteroids may improve outcome in dogs with nonresectable GI pythiosis. This report describes 3 dogs with colonic pythiosis in which complete resolution of clinical signs, regression of colonic masses, and progressive decreases in serological titers were observed after treatment with itraconazole, terbinafine, and corticosteroids. This treatment protocol represents a promising treatment for dogs with GI pythiosis in which surgical intervention is not feasible.
| INTRODUCTION
The aquatic oomycete Pythium insidiosum is the causative agent of pythiosis, a severe, progressive, and often fatal disease that most often affects the skin or gastrointestinal (GI) tract in dogs. 1 Although historically it has been diagnosed in tropical and subtropical regions, 2 its geographical distribution in the United States has expanded over the past 15 years to include more arid environments in California and
Arizona and less temperate climates in Wisconsin. 3, 4 Gastrointestinal pythiosis typically causes focal or multifocal segmental thickening or expansile granulomatous masses involving the stomach, small intestine, colon, and, less often, the esophagus. 3, [5] [6] [7] [8] Areas of the GI tract that most often are affected include the gastric outflow region and the ileocecocolic junction (ICCJ).
Treatment of GI pythiosis traditionally has been unrewarding, likely because ergosterol (the target of most traditional antifungal drugs) generally is lacking in the oomycete cell membrane. 9 Instead, as sterol auxotrophs, Pythium, Lagenidium, and related oomycetes incorporate sterols from their environments or hosts rather than producing them. 9 Nonetheless, improvement or resolution of clinical disease has been described after treatment with ergosterol-targeting drugs (most often itraconazole and terbinafine) in a small number of dogs with pythiosis as well as in a 2-year-old child. 5, [10] [11] [12] Despite these limited successes, the prognosis for dogs with nonresectable GI pythiosis has for the most part remained poor, with a reported median survival time of 26.5 days. 3, 5 Recently, however, it was noted that the addition of anti-inflammatory doses of prednisone to antifungal treatment in an effort to palliate clinical signs may Hospital with a 1-month history of large bowel diarrhea, hematochezia, tenesmus, dyschezia, and weight loss. The dog was adopted 1 month before presentation and the previous medical history was unknown.
General physical examination showed a body condition score (BCS) of 2 out of 9 and slight tachycardia. Body weight on presentation was Anti-P. insidiosum antibody serology was monitored every 6-12 months and continued to be 13%-26% PP. Two years after diagnosis, serology monitoring became unavailable from the initial laboratory and continued serologic monitoring was performed using an alternative laboratory (Pythium Laboratory, Pathobiology Diagnostic Services, Auburn University, Auburn, Alabama). Five years after diagnosis, the dog's anti-P. insidiosum antibody serology was 6% PP and the dog was still receiving itraconazole, terbinafine, and prednisone at the same doses described above.
3 | CASE 2 Surgical treatment with excision of the diseased distal colon and rectal pull-through procedure were recommended but declined by the owners, and medical treatment was initiated with prednisone (0.5 mg/kg PO q12h for 2 weeks then decreased to q24h for 2 months), itraconazole (10 mg/kg PO q24h) (generic noncompounded itraconazole), and terbinafine (12 mg/kg PO q24h) (generic noncompounded terbinafine).
At reevaluation 1 month after starting medical treatment, the owners reported complete cessation of clinical signs within 1 week after initiating treatment. Rectal examination indicated complete resolution of the rectal masses, and a repeat CBC was unremarkable. Anti-P. insidiosum antibody serology was 65% PP (Pythium Laboratory, Pathobiology Diagnostic Services, Auburn University). A follow-up abdominal ultrasound examination after 2 months of treatment was unremarkable, with resolution of the previously noted colic lymphadenomegaly.
Prednisone was tapered between months 2 and 5 of treatment by 25% once monthly and then discontinued. Anti-P. insidiosum antibody serology was reevaluated after 3, 5, 7, and 10 months of treatment with results of 22% PP, 19% PP, 21% PP, and 21% PP, respectively. After 12 months of treatment, the dog remained clinically normal with normal rectal examination and abdominal ultrasonography findings, and antifungal medications were discontinued. One month after discontinuing itraconazole and terbinafine, the dog did not show any clinical signs, abdominal ultrasound examination was unremarkable, and anti-P. insidiosum antibody serology was 21% PP (Pythium Laboratory, Pathobiology Diagnostic Services, Auburn University).
| DISCUSSION
Few single case reports have documented treatment success with marginal surgical excision and medical treatment using a combination of potassium iodide, itraconazole, and terbinafine, 15 or Pythium immunotreatment, itraconazole, and terbinafine. 11 Another case report described a positive response to medical treatment without surgical resection in a dog with gastric pythiosis after administration of itraconazole, terbinafine, and mefonoxam. 10 It is difficult to determine whether surgical or medical intervention, or a combination of both, was responsible for the favorable outcomes in these dogs, but these results do indicate that combination treatment could be superior to itraconazole monotherapy.
Triazole and squalene epoxidase inhibitors inhibit fungal ergosterol synthesis, but Pythium lacks ergosterol in its cell membrane. 9, 16 One previous in vitro investigation failed to show susceptibility of P. insidiosum to itraconazole and showed only weak susceptibility to terbinafine, which may be a consequence of intracellular accumulation of squalene rather than ergosterol inhibition. 17 Another study as well as a single case report in a human patient showed synergism between terbinafine and itraconazole (as was used in the 3 dogs presented here) for some strains of P. insidiosum, 12,18 but other in vitro reports have not noted this synergism.
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The 3 dogs described here were treated with anti-inflammatory doses of prednisone in addition to the antifungal medications itraconazole and terbinafine. The inclusion of prednisone in combination with antifungal treatment is a novel treatment modality in dogs with GI pythiosis that has been used to palliate severe clinical signs in affected dogs with the observation that some of these dogs had complete resolution of pythiosis. 1 Corticosteroids are an important adjunct treatment for some pulmonary mycotic infections and for histoplasmosis in people and systemic mycoses in dogs. [20] [21] [22] [23] [24] This treatment is counterintuitive, because high dose or long-term corticosteroid treatment is associated with immunosuppression and predisposes patients to opportunistic fungal infections, 25 but lower anti-inflammatory dosages appear to improve outcomes. Pythiosis is a highly inflammatory disease as indicated by the dense cellular infiltrates noted on histopathology of colonic biopsy specimens. Eosinophilic inflammation is a hallmark of GI pythiosis and likely contributes to the severe clinical signs noted in these dogs. Eosinophils are highly sensitive to the effects of corticosteroids including decreased adherence, inhibited chemotaxis and apoptosis, and these effects may explain why corticosteroids lead to clinical improvement in dogs with GI pythiosis. 26, 27 The degree to which each of the individual treatments used in these 3 patients contributed to the resolution of disease is unknown, especially given that in our previous experience patients have been clinically cured treated with corticosteroids alone or with itraconazole and terbinafine in combination in the absence of corticosteroids. Case 2 was the only dog to undergo measurement of antifungal drug concentrations which were below the limit of detection of the bioassay.
This finding may indicate that the prednisone was larger a greater role in the improvement in clinical signs than the anti-fungal medications in the early stages of treatment.
Anti-P. insidiosum antibody serology gradually decreased in all 3 dogs and became negative after 3 to 4 months of combination treatment. These results are similar to those previously reported in dogs that have been successfully treated by complete surgical resection. 14 Treatment with corticosteroids could have resulted in serologic titer decrease without disease resolution, but antibody serology continued to decrease after discontinuation of corticosteroids in Cases 2 and 3. During the courses of treatment for Cases 1 and 2, the ELISA that was previously validated with sensitivity and specificity both of 100% 14 became unavailable and samples were submitted to an alternate diagnostic laboratory (Pythium Laboratory, Pathobiology Diagnostic Services, Auburn University). The second assay uses a protocol similar to that developed for the first assay; however, the P. insidiosum antigen used in the assay includes both secreted proteins and whole-cell extract in the latter assay, whereas the former assay utilized only whole-cell extract (personal communication, P. Barger).
Although published information on sensitivity and specificity for the second assay is not available, sensitivity and specificity are expected to be similar to those of the first assay.
The medical approach presented here offers promise for dogs 
